GSK plc
GLAXF
$19.03
$0.14340.76%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.42% | 4.13% | 6.26% | 9.08% | 12.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.42% | 4.13% | 6.26% | 9.08% | 12.16% |
| Cost of Revenue | 7.60% | 7.08% | 8.34% | 2.56% | 3.03% |
| Gross Profit | 1.86% | 3.02% | 5.46% | 11.79% | 16.00% |
| SG&A Expenses | 20.22% | 20.07% | 19.34% | 22.62% | 7.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 57.49% | 71.12% | 73.55% | 24.92% | -35.32% |
| Total Operating Expenses | 15.71% | 16.54% | 17.94% | 14.60% | 6.77% |
| Operating Income | -27.00% | -27.20% | -24.24% | -6.77% | 28.19% |
| Income Before Tax | -5.72% | -23.02% | -41.54% | -53.70% | -19.76% |
| Income Tax Expenses | -7.52% | -22.05% | -29.09% | -41.58% | -2.56% |
| Earnings from Continuing Operations | -5.42% | -23.18% | -43.32% | -55.15% | -22.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -103.71% | -81.09% | -2.16% | 23.08% | 27.41% |
| Net Income | -13.09% | -29.53% | -46.81% | -57.52% | -72.22% |
| EBIT | -27.00% | -27.20% | -24.24% | -6.77% | 28.19% |
| EBITDA | -7.85% | -11.34% | -11.51% | -1.71% | 17.17% |
| EPS Basic | -13.33% | -29.99% | -47.12% | -57.78% | -72.43% |
| Normalized Basic EPS | -35.29% | -34.56% | -27.59% | -4.45% | 38.32% |
| EPS Diluted | -13.29% | -29.89% | -47.11% | -57.72% | -72.39% |
| Normalized Diluted EPS | -35.31% | -34.54% | -27.52% | -4.43% | 38.26% |
| Average Basic Shares Outstanding | 0.33% | 0.59% | 0.62% | 0.61% | 0.61% |
| Average Diluted Shares Outstanding | 0.43% | 0.68% | 0.70% | 0.68% | 0.65% |
| Dividend Per Share | 7.93% | 6.66% | 8.08% | 13.06% | 12.98% |
| Payout Ratio | 0.25% | 0.59% | 1.10% | 1.51% | 2.60% |